The final version of HTA Core Model® and the Methodological Guidelines for Rapid REA of Pharmaceuticals is now available

They have been produced between January 2010 and February 2013 by Work Package 5 (WP5) of the Joint Action 1 (2010-2012) as part of the objective to “develop HTA tools and methods for improved relative effectiveness assessments”. The Model and the Guidelines will be tested in pilot assessments in WP5 Joint Action 2 (2012-2015).

The HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals 

This Model is a specific application of The HTA Core Model® adapted for the rapid assessment of the relative effectiveness of pharmaceuticals. The Model is a tool that defines the content elements to be considered in a rapid REA and facilitates standardised reporting. The aim of the use of the Model is to share information, to avoid duplication of work, and to facilitate the adaptation of information in national REA reports and the co-production of REA reports (by multiple HTA agencies).

The Model and the Guidelines will be tested in pilot assessments in WP5 Joint Action 2 (2012-2015). Based on the experience gained in these pilots the current version of the Model will be updated in 2015.

• Please find the Model by following this link:

HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals

.

The Model was open for public consultation from 1 October 2012 to 30 November 2012.

• Please find the document containing comments & responses of the HTA Core Model by following this link:

Public consultation on HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals

.

The Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals

Methodological Guidelines for Rapid REA of Pharmaceuticals are guidelines on methodological challenges that are encountered by health technology assessors while performing a rapid relative effectiveness assessment of pharmaceuticals. The primary aim of the guidelines is to help the assessors of evidence interpret and process the data that are presented to them as part of a REA.  The following 9 guidelines have been developed grouped within three themes:

Endpoints used for REA of pharmaceuticals

:

• Clinical endpoints
• Composite endpoints
• Surrogate endpoints
• Safety
• Health-related quality of life

Comparators and comparisons

• Criteria for the choice of the most appropriate comparator(s)
• Direct and indirect comparison

Levels of evidence

• Internal validity
• Applicability of evidence in the context of a relative effectiveness assessment

The Guidelines were open for public consultation between June and October 2012.

• Please find the document of comments and responses by following this link:

The public consultation of the Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals